Selective FFA2 Agonism Appears to Act via Intestinal PYY to Reduce Transit and Food Intake but Does Not Improve Glucose Tolerance in Mouse Models.

@article{Forbes2015SelectiveFA,
  title={Selective FFA2 Agonism Appears to Act via Intestinal PYY to Reduce Transit and Food Intake but Does Not Improve Glucose Tolerance in Mouse Models.},
  author={Sarah Forbes and Stuart Stafford and Gareth Coope and Helen Heffron and Katia Real and Robert Newman and Richard Davenport and Matt Barnes and Johannes Gro\sse and Helen E Cox},
  journal={Diabetes},
  year={2015},
  volume={64 11},
  pages={3763-71}
}
Free fatty acid receptor 2 (FFA2) is expressed on enteroendocrine L cells that release glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) when activated by short-chain fatty acids (SCFAs). Functionally GLP-1 and PYY inhibit gut transit, increase glucose tolerance, and suppress appetite; thus, FFA2 has therapeutic potential for type 2 diabetes and obesity. However, FFA2-selective agonists have not been characterized in vivo. Compound 1 (Cpd 1), a potent FFA2 agonist, was tested for its… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Ligands at the Free Fatty Acid Receptors 2/3 (GPR43/GPR41).

Handbook of experimental pharmacology • 2017
View 6 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery.

Current opinion in pharmacology • 2013
View 7 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…